An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).

John Victor Heymach,Michael Thomas,Benjamin Besse,Patrick M. Forde,Mark M. Awad,Glenwood D. Goss,Keunchil Park,Naiyer A. Rizvi,Si-Houy Lao-Sirieix,S. Patel,Peter G. Mortimer,Helen Ambrose,Philip J. Jewsbury,Kris Sachsenmeier,Leila Khoja,Wolfram Brugger

An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).

2018

John Victor Heymach
Michael Thomas
Benjamin Besse
Patrick M. Forde
Mark M. Awad
Glenwood D. Goss
Keunchil Park
Naiyer A. Rizvi
Si-Houy Lao-Sirieix
S. Patel
Peter G. Mortimer
Helen Ambrose
Philip J. Jewsbury
Kris Sachsenmeier
Leila Khoja
Wolfram Brugger

TPS3120Background: Immune checkpoint inhibitor (ICI) containing regimens have significantly improved survival outcomes in first- and second-line non-small cell lung cancer (NSCLC). However, the maj...

Keywords:

Pathology
PD-L1
Biomarker (medicine)
Lung cancer
Medicine
open label
improved survival
in patient
Oncology
Internal medicine
non small cell
anti pd 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations